A-SEEDS Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$16.4M
- Investors
-
11
A-SEEDS General Information
Description
Operator of a medical research company intended to focus on the realization and commercialization of CAR-T therapy. The company aims to commercialize gene therapy using GMR-CAR and focus on the research and development of new CAR-T therapies, supply of raw materials to popularize CAR-T therapy, as well as implement technical guidance on cell culture, enabling the medical community to have assistance in the practical application of CAR-T therapy.
Contact Information
Website
www.a-seeds.co.jpCorporate Office
- 3-1-1 Asahi Matsumoto
- Number 206 CSMIT
- Matsumoto, 390-0802
- Japan
Corporate Office
- 3-1-1 Asahi Matsumoto
- Number 206 CSMIT
- Matsumoto, 390-0802
- Japan
A-SEEDS Timeline
A-SEEDS Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series A) | 07-Jul-2025 | $16.4M | Completed | Clinical Trials - Phase 2 | ||
| 1. Seed Round | 04-Jan-2024 | Completed | Clinical Trials - Phase 2 |
A-SEEDS Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class A Preferred | ||||||||
| Class A4 Preferred | ||||||||
| Class A3 Preferred | 77,821 | $3.55 | $3.55 | 1x | $3.55 | 1.59% | ||
| Class A-2 Preferred | 393,700 | $3.51 | $3.51 | 1x | $3.51 | 8.02% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
A-SEEDS Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
A-SEEDS Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
A-SEEDS Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Capital Medica Ventures | Corporate Venture Capital | Minority | ||
| Delight Ventures | Venture Capital | Minority | ||
| Itochu Enex | Corporation | Minority | ||
| KSP (Other Commercial Products) | Corporation | Minority | ||
| Mizuho Capital | Venture Capital | Minority |
A-SEEDS FAQs
-
When was A-SEEDS founded?
A-SEEDS was founded in 2020.
-
Where is A-SEEDS headquartered?
A-SEEDS is headquartered in Matsumoto, Japan.
-
What is the size of A-SEEDS?
A-SEEDS has 21 total employees.
-
What industry is A-SEEDS in?
A-SEEDS’s primary industry is Drug Discovery.
-
Is A-SEEDS a private or public company?
A-SEEDS is a Private company.
-
What is the current valuation of A-SEEDS?
The current valuation of A-SEEDS is .
-
What is A-SEEDS’s current revenue?
The current revenue for A-SEEDS is .
-
How much funding has A-SEEDS raised over time?
A-SEEDS has raised $19.5M.
-
Who are A-SEEDS’s investors?
Capital Medica Ventures, Delight Ventures, Itochu Enex, KSP (Other Commercial Products), and Mizuho Capital are 5 of 11 investors who have invested in A-SEEDS.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
